An international research collaboration between Australia and the USA, led by Associate Professor Roscioli at NeuRA has identified new genes that cause cleft lip and palate. The genes, associated for the first time with cleft lip and palate, encode proteins that work together in a network, providing important insights into the biological basis of one of the most common physical malformations.
Representing about 70 per cent of cleft lip and palate cases worldwide, non-syndromic cleft lip and palate typically occurs in isolation without other physical abnormalities. This craniofacial malformation has long been considered to be caused by a combination of many common genetic variants and environmental factors, each contributing a small amount to the risk of a child being born with a cleft.
Using next generation sequencing, the research team identified variants in four new genes, each representing a primary cause of non-syndromic cleft lip and palate. Variants in these genes were found to account for 15 per cent of the families who took part in the study and in nearly three per cent of a second, larger group of smaller families and isolated cases.
Published in the American Journal of Human Genetics, the study provides the first evidence that a significant number of non-syndromic clefts have a single gene basis and not a complex basis as previously thought.
Associate Prof Tony Roscioli said cleft lip/palate is one of the most common human malformations, occurring in one in 800 children.
“That equates to about 250 Australian children each year and one affected child born every three minutes worldwide,” said Associate Prof Roscioli.
“Knowing the genes and the way these impact lip and palate formation opens the door for further research to understand how these genes work and to develop treatments.”
Cleft lip and cleft palates are repaired with corrective surgery. Future research will investigate the biology and link the findings to potential therapies. These discoveries will allow geneticists to provide more accurate information to families.
Associate Professor Tony Roscioli is a specialist in clinical genetics at the Sydney Children’s Hospital and leads the Sydney Partnership for Health Education Research and Enterprise (SPHERE) GenomeConnect clinical academic stream. At NeuRA he leads the Centre for Research Excellence in Neurocognitive Disorders where he endeavours to transform the diagnosis and management of intellectual disability through genomics.
More than 80,000 people are living with Parkinson’s disease in Australia, and of these, approximately two thirds will fall each year. Ensuing injuries, hospitalisations, fear of falling and caregiver burden are devastating, widespread and costly. As the prevalence of Parkinson’s disease will double between 2010 and 2040, the associated human and economic burden will also grow. Innovative therapies to improve […]